Impedimed Ltd has released a press release.
Meta-Analysis-BIS L-Dex Statistically Significant Reduction
Filed with ASX ·
Watch Impedimed's latest callImpedimed (ASX:IPD) Q1 2027 Earnings Call · Replay · Oct 29Read the transcript of Impedimed (ASX:IPD) Q1 2027 Earnings Call6ix hasn’t read this filing yet.
Earlier from Impedimed
- ImpediMed Secures First Commercial Heart Failure Sales
- AstraZeneca Selects SOZO for Second Large Renal Trial
- Landmark Radiation Manuscript Supports L-Dex Use
- Appendix 4C - Quarter ended 30 September 2020
- AstraZeneca Selects SOZO for Heart Failure & Renal Trials
Later from Impedimed
- Option Exercise and Preliminary Quarterly Cash Flow Results
- PREVENT Trial Finishes, Final Patient Completes Follow-up
- Appendix 4C - Quarter ended 31 December 2020
- American College of Cardiology Accepts SOZO HF Abstract
- Appendix 4D - Half-Year Results Ended 31 December 2020
Follow Impedimed into a list and get an email when it puts out news.
Follow Impedimed